United States Liquid Biopsy Market Set for Breakthrough Growth with Rising Demand for Non-Invasive Cancer Diagnostics 2025 | Major key players - Guardant Health, Qiagen, Thermo Fisher Scientific.

Market Size and Growth:

The Global Liquid Biopsy Market size reached US$ 9.07 billion in 2024 and is expected to reach US$ 25.19 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

The Liquid Biopsy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/liquid-biopsy-market?sz

The Liquid Biopsy Market refers to the segment of healthcare focused on non-invasive diagnostic tests that analyze blood or other body fluids to detect cancer, genetic mutations, and other diseases. It enables early detection, monitoring of disease progression, and treatment response assessment, offering a faster, safer, and more convenient alternative to traditional tissue biopsies.

Recent Key Developments of United States (U.S):

FDA Breakthrough Device Designation: Haystack MRD, a circulating tumor DNA (ctDNA) liquid biopsy test from Quest Diagnostics, received a Breakthrough Device Designation from the FDA in August 2025. This designation is for identifying patients with stage II colorectal cancer who have minimal residual disease (MRD) and may benefit from adjuvant therapy after surgery.

Product Launch: In September 2025, Exact Sciences launched "Cancerguard," a new liquid biopsy test designed to screen for over 50 different types of cancer from a single blood sample.

Strategic Partnerships: Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration in September 2025 to develop a global liquid biopsy companion diagnostic test for pharmaceutical companies. The partnership aims to combine Myriad's lab capabilities with SOPHiA GENETICS' AI platform.

Clinical Trial Results: Natera announced positive topline results from its IMvigor011 trial, which showed that its Signatera test could predict the benefit of adjuvant immunotherapy in patients with muscle-invasive bladder cancer.

New Diagnostic Launches: NeoGenomics launched its NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test in August 2025, to aid in therapy selection, clinical trial matching, and monitoring.

List of the Key Players in the Liquid Biopsy Market:

Exosome Sciences Inc
Illumina, Inc
Guardant Health
Thermo Fisher Scientific Inc
NeoGenomics Laboratories
Qiagen
BioChain Institute Inc
Sysmex Europe SE
Eurofins Genomics
Goffin Molecular Technologies

Emerging Market Players:

Exact Sciences
Tempus
Dxcover Limited

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=liquid-biopsy-market

Segments Covered in the Liquid Biopsy Market:

By Product Type: Kits & Reagents, Instruments, Services.

By Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Extracellular Vesicles.

By Application: Cancer Applications, Non-Cancer Applications.

By Technology: Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays).

By End User: Hospitals and Physician Laboratories, Research Centers, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/liquid-biopsy-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Liquid Biopsy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Liquid Biopsy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Liquid Biopsy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Liquid Biopsy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Liquid Biopsy Market in 2025?
◆ What is the projected growth rate of the Liquid Biopsy Market through 2033?
◆ Who are the key players in the Liquid Biopsy Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.